Founded in October 2010, as a spin-off of the Liège University in Belgium, ARTIALIS became a first-mover biotech company specialized in the development and the clinical application of biomarkers-based immunoassays and trials. Our mission is to develop personalized solutions based on specific and innovative biomarkers for the diagnosis, the prognosis and the follow-up of musculoskeletal disorders. ARTIALIS capitalizes on innovation, dynamism, creativity, and ethics to become a leader of the joint health market.

1. APRIL 2015
YOUR PARTNER FOR INNOVATION IN
MUSCULOSKELETAL DISEASE

2. WHO WE ARE
Our vision
To be a leader of the joint health market offering personalized innovative solutions to address unmet
needs in the musculoskeletal field
Our mission
To develop personalized solutions based on specific and innovative biomarkers for the research
and management of musculoskeletal disorders
Our values
Professionalism, dynamism, creativity, and ethics
Our strength
A diversity of talents working together: 15 people with complementarity expertise in musculoskeletal field

3. WHAT WE DO
IN THE FIELD OF
MUSCULOSKELETAL
DISEASES
ELISA KITS
RUO & CE-IVD
CLINICAL
TRIAL
PRECLINICAL
STUDIES
DESIGN &
DEVELOPMENT
OF
BIOMARKERS
INNOVATIVE
BIOMARKERS

4. BIOMARKER IS CLASSICALLY DEFINED AS A CHARACTERISTIC THAT IS OBJECTIVELY MEASURED AND
EVALUATED AS AN INDICATOR OF NORMAL BIOLOGIC PROCESSES, PATHOGENIC PROCESSES, OR
PHARMACOLOGICAL RESPONSES TO A THERAPEUTIC INTERVENTION.
(BIOMARKERS DEFINITIONS WORKING GROUP, CLIN PHARMACOL THER 2001;69:89-95)
THE CORE OF OUR ACTIVITIES
CARTILAGE METABOLISM
INFLAMMATION
BONE REMODELING
MATRIX DISORGANIZATION
CUSTOMIZED TO DRUG:
COMPANION KIT
INNOVATIVE BIOMARKERS

5. HIGHLIGHT ON CARTILAGE METABOLISM: COLL2-1
Coll2-1 is a specific fragment of type II collagen
Type II collagen is the main component of the articular cartilage
Coll2-1 immunoassay is available in blood and urine samples
INNOVATIVE BIOMARKERS

6. FOR THE DIAGNOSIS, THE
PROGNOSIS, AND THE FOLLOW-UP
OF OSTEOARTHRITIS
INNOVATIVE BIOMARKERS

7. BUT ALSO…
ARTIALIS OFFERS A COMPLETE PORTFOLIO OF VALIDATED BIOMARKERS EITHER AS ELISA KIT OR THROUGH
BIOMARKER TESTING SERVICE
BONE
Osteocalcin
NTXI
CARTILAGE
Coll2-1
CTXII
Aggrecan
Fibulin-3
COMP
INFLAMMATION
Coll2-1NO2
PGE2
usCRP
MPO
HA
METALLOPROTEASES
MMP1
MMP3

8. PRECLINICAL STUDIES
ONE-STOP SOLUTION
ANALYSIS OF
YOUR NEEDS
FIRST, WE MEET!
STUDY DESIGN
•Animal model
•Time line
•Treatment
administration
•Biomarkers
IN-LIFE PHASE
•Clinical follow-up
•Blood sampling
•Surgery
•Imaging
•Treatment
administration
EX-VIVO
EXPERIMENTS
•Macroscopy
•Histology
ANALYSE
AND
STATISTICS
REPORT

9. PRECLINICAL STUDIES
ANIMAL MODELS
• Rat, rabbit, guinea pig,…
• Induced OA model
• Spontaneous OA model
STUDY ENDPOINTS
• Gold standard endpoints
• Macroscopy
• Histology
INNOVATIVE TOOLS
• Biomarkers
• CatWalk
• Mach 1

10. CLINICAL TRIALS
WE CAN OFFER AN ALL-IN-ONE COST-EFFECTIVE CLINICAL TRIAL INCLUDING BIOMARKERS, X-RAY AND
MAGNETIC RESONANCE IMAGING (MRI) ANALYSES
ONE-STOP SOLUTION
• SAFETY
• EFFICACY
• FOOD COMPLEMENT
• VISCOSUPPLEMENTATION
• BIOMARKERS QUALIFICATION
• BIOLOGICAL VARIABILITY
• …
FROM
EXPLORATORY
TO
POST-MARKETING

11. CLINICAL TRIALS
CLINICAL CRO
(FULL SET OF
SERVICES)
STUDY
DESIGN
PROTOCOL
WRITING
KOL
EXPERTISE
TRIAL
ESSENTIAL
DOC
REGULATORY
ACTIVITIES
SITE
SELECTION
MONITORING
BIOMARKERS
TESTING
IMAGING OA
MARKERS
DATA
MANAGEMENT
STATISTICS
FINAL
REPORT
 Evaluation of the Prognostic Value of Biological Markers, Coll2-
1 and Coll2-1NO2 in Patients With Symptomatic Knee
Osteoarthritis (PRODIGE) NCT02070224
 Biological Variability in Cartilage Specific Biomarkers in Healthy
Volunteers (COVAR) NCT02348944

12. IMAGE READING
- WORMS
- T2 MAPPING
- VOLUME
TRANSFER
QUALITY
CONTROL
Protocol design
Site selection
- Multi-site imaging coordination
- Imaging parameters standardization
- Site training
Transfer to central
reading
Quality assurance
Selection, training validation
and monitoring of expert
radiologists specialized in
osteo-articular disease
Highlight on clinical imaging: MRI
CLINICAL TRIALS

13. IN SILICO ANALYSIS
• Review of literature
• Bioinformatics'
analysis
• Peptide design
• IP assessment
• Immunoassay type
TOOLS PRODUCTION
& SELECTION
• Immunogen
• Animals
• Hybridoma
• Cloning steps
• Production and
purification Abs
• Qualification of Ab
(titer, specificity)
IMMUNOASSAY
DEVELOPMENT &
VALIDATION
• Assay protocol
• Dynamic range
• Analytical
performances
BIOMARKER
QUALIFICATION
• Preclinical studies
• Artialis’ proprietary
cohorts (COVAR,
PRODIGE)
• Collaborative
cohorts
• New clinical trial
specifically designed
COMPANION
KIT
• Industrialization
• Scale-up
SUPPORT TO DESIGN & DEVELOPMENT
TAILOR-MADE SOLUTION
FROM DESIGN TO COMPANION KIT, YOUR PARTNER AT EACH STEP FOR THE DEVELOPMENT OF YOUR
CUSTOMIZED BIOMARKER

14. WHERE WE ARE
ARTIALIS IS LOCATED INSIDE THE UNIVERSITY HOSPITAL OF LIÈGE
+32 4 242 77 27
contact@artialis.com
ARTIALIS s.a
11, Avenue de l'Hôpital
Tour GIGA +3
4000 Liège (Sart-Tilman)
Belgium